Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04543279 · ClinicalTrials.gov registry record · Phase 2
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04543279 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 3 participants.
The verdict
NCT04543279, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Fostamatinib may improve thrombocytopenia in myelofibrosis patients with severe thrombocytopenia (platelet \<50,000/microL) and allow them to initiate treatment with a JAK2 inhibitor, ruxolitinib. Additionally, fostamatinib monotherapy may also improve myelofibrosis related symptoms and splenomegaly.
Interventions
- DRUG Ruxolitinib
- DRUG Fostamatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-05-03 |
| Est. Completion | 2022-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04543279
The ClinicalTrials.gov registry entry for NCT04543279 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT04543279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04543279 about?
NCT04543279 is a clinical study titled "Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia". Fostamatinib may improve thrombocytopenia in myelofibrosis patients with severe thrombocytopenia (platelet \<50,000/microL) and allow them to initiate treatment with a JAK2 inhibitor, ruxolitinib. Additionally, fostamatinib monotherapy may also improve myelofibrosis related symptoms and splenomegaly...
What is the current status of trial NCT04543279?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2021-05-03. Estimated completion is 2022-07-30.
What interventions are being tested in trial NCT04543279?
The interventions under investigation include: Ruxolitinib (DRUG), Fostamatinib (DRUG).
Who is sponsoring clinical trial NCT04543279?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.